BioXcel Therapeutics Executives, Vimal Mehta and Vince O’Neill, discuss how they are actively using artificial intelligence to discover advanced therapies in CNS and oncology.
Alex Neumeister
Advertisement
Articles by Alex Neumeister
COO and CMO of BrainStorm, Ralph Kern, discusses how his company is overcoming challenges and advancing science in neurodegenerative disease.
Dr. Steven Fox, CEO of Akelos Inc., discusses the challenges of developing new non-opioid medical products as the need intensifies as the crisis worsens.
Dr. Daniel Alkon, President & Chief Science Officer at Neurotrope, discusses novel approaches to AD therapy development and why his company chose to target patients with advanced AD for their own.
Advertisement
Latest Updated Articles
Alzheimer’s Disease Research Finds New BeginningsPublished: August 22nd 2019 | Updated:
Emerging Biopharma Tackles the Opioid CrisisPublished: September 12th 2019 | Updated:
Overcoming the Complexities of Neurodegenerative Clinical TrialsPublished: September 25th 2019 | Updated:
Pharma Companies Use AI to Advance Drug DevelopmentPublished: October 4th 2019 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Praxis Reports Positive Phase III Results for Ulixacaltamide in Essential Tremor
2
Imfinzi Plus FLOT Significantly Improves Overall Survival in Gastric and Gastroesophageal Cancer
3
Applied Clinical Trials: October 2025 Interactive Digital Edition
4
Adaptive Trial Design as a Pathway to Faster Development
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
